The pathophysiology of uterine adenomyosis: an update

Benagiano, Giuseppe; Habiba, Marwan; Brosens, Ivo

doi:10.1016/j.fertnstert.2012.06.044

Cited by 158 publications

(135 citation statements)

References 104 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…3 Although the etiology and pathophysiology of adenomyosis are not well understood, there are several hypotheses that have been suggested. 4 The presence of a more invasive endometrium has been exhibited; when grown on a plain collagen matrix, stromal cells from adenomyosis have shown greater invasiveness compared with normal stromal cells. 5 Differences have also been observed in smooth muscle cells from adenomyosis, where myocytes exhibit cellular hypertrophy.…”

Section: Introductionmentioning

confidence: 99%

MR-guided focused ultrasound for the treatment of adenomyosis: current insights

Chin¹,

Walbridge²,

Quinn³

2015

RRFU

View full text Add to dashboard Cite

Adenomyosis is a benign gynecological condition causing significant morbidity among women of reproductive age. The available treatments are currently limited in number and efficacy. While hysterectomy is curative, it is unacceptable to many women, particularly those wishing to conserve their fertility. Magnetic resonance-guided focused ultrasound surgery is a noninvasive treatment method that has been used to effectively treat uterine leiomyomata, but until recently has not been routinely used to treat adenomyosis. This review summarizes the current understanding of adenomyosis and high-intensity focused ultrasound, and the recent research into the safety and efficacy of this technique.

show abstract

Section: Introductionmentioning

confidence: 99%

MR-guided focused ultrasound for the treatment of adenomyosis: current insights

Chin¹,

Walbridge²,

Quinn³

2015

RRFU

View full text Add to dashboard Cite

show abstract

“…10 Dosing in each cohort occurred sequentially. Dose escalation proceeded once preliminary safety/tolerability (days [1][2][3][4][5][6][7][8][9][10][11][12][13][14] and PK data (days 1 and 7) had been reviewed for all subjects at the previous dose. Blood samples for safety and PK analysis were collected on days 1, 7, and 14 of the 14-day in-house treatment period.…”

Section: Multiple-day Dosing Studymentioning

confidence: 99%

“…1 Patients with adenomyosis are primarily premenopausal and may experience heavy menstrual bleeding, severe dysmenorrhea, pelvic pain, and/or dyspareunia. 2 In addition, the presence of adenomyosis has been implicated in impaired reproductive function including infertility, in vitro fertilization failure, idiopathic spontaneous abortions, and other adverse pregnancy outcomes.…”

mentioning

confidence: 99%

Single‐ and Multiple‐Day Dosing Studies to Investigate High‐Dose Pharmacokinetics of Epelsiban and Its Metabolite, GSK2395448, in Healthy Female Volunteers

Mahar

Enslin

Gress

et al. 2017

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

Open-label single-and double-blind repeat-dose studies in healthy female volunteers were conducted to investigate the pharmacokinetics (PK) and safety/tolerability of epelsiban total daily doses ranging from 600 to 900 mg. In 1 study (n = 12), epelsiban was dosed at 300 or 450 mg twice daily (every 12 hours) for a single day. In the repeat-dose doubleblind study, epelsiban and placebo were administered to 31 subjects as 200 mg 3 times daily, 300 mg 3 times daily (TID), or 450 mg twice daily (BID) for 14 days. After both single and 14 daily repeat doses, the PK profiles for epelsiban and its metabolite, GSK2395448, remained linear at all administered doses. The exposures at a given total daily dose were also similar between BID and TID dosing regimens. Exposure (AUC 0-τ ), based on dosing intervals, for both epelsiban and GSK2395448 was similar. However, compared with morning dosing, C max was lower after evening dosing, possibly because of a food effect. The highest accumulation of epelsiban and GSK2395448 exposures (AUC 0-τ ) was approximately 34% for each after repeat dosing, consistent with the short half-life. At total daily doses of 600 and 900 mg, epelsiban was generally well tolerated, and there were no significant safety concerns identified.

show abstract

“…Незважаючи на значне число наукових публі-кацій з проблем ендометріозу і гіпотиреозу окремо, наукові дослідження, що стосуються взаємозв′язку цих двох патологій, практично відсутні, а наявні по-одинокі публікації носять фрагментарний характер [2,3,10]. Усе викладене вище свідчить про актуаль-ність вказаної наукової проблеми.…”

Section: обґрунтування дослідженняunclassified